Rockford Coscia
Contributor since: 2010
Latest Articles
Vivus Planning for Failure in Qnexa Birth Defect Study
Xenoport Expecting GERD Study Data
MannKind Is Teetering on the Brink of Disaster
NDA Decision Delay May Be Good for MannKind, Not for Human Genome Sciences
Arena Completes End-Of-Review Meeting With FDA
Clinical Data's Vilazodone Offers Possible Blockbuster Returns
Orexigen's Contrave Obesity Drug Heads to FDA Panel: Analyzing the Safety Issues
Buyout or No, Delcath Offers a Valuable Investment Opportunity
Avanir's AVP-923: Is QTc Prolongation Above 'Threshold of Concern'?
What Amylin's Diabetes Treatment Complete Response Letter Means for Avanir
Alexza's CRL Offers Long Term Investment Opportunity
Alexza Pharmaceuticals: Hold, Sell, Or Put?
Biodel: Upside from Potential Linjeta Approval
Vivus' Qnexa Panel: What Might Have Been
Avanir: Insider Selling and Shelf Registration Are No Big Deal
Avanir Pharma's Pending FDA Approval: The Upside Potential
Arena's Lorcaserin: What Now?
Arena Pharmaceutical's Lorqess: A Briefing Document Analysis
Arena's Lorqess: A Market Size Analysis
Vivus' Qnexa Panel Bodes Well for Arena's Obesity Drug
Five Potential Small Cap Biotech Bargains
Why Cumberland Pharma Needs Acetadote Approval to Avert Disaster
A Reintroduction to Savient's Krystexxa
Arena's Obesity Drug Likely to Pass FDA Panel With Flying Colors
Jazz: Your FDA Panel Primer
Will MannKind's Afrezza Succeed Where Pfizer's Exubera Failed?